NASDAQ:RNXT

Renovorx Stock Insider Trading

Healthcare > Biotechnology

Buy RNXT

*Your capital is at risk

$0.96

+0.0171 (+1.82%)

At Close: Jul 31, 2026

RenovoRx Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.01M and sold 800K RNXT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	6.01M shares
● Sell	800K shares
98% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Apr 06, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (98% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 08, 2025 Buy	Common Stock P-Purchase	Marton Laurence Director	Director	12 050 Value: $10.2K
Apr 08, 2025 Buy	Common Stock P-Purchase	Marton Laurence Director	Director	12 050 Value: $10.2K
Apr 08, 2025 Buy	Common Stock P-Purchase	Agah Ramtin Chief Medical Officer	Officer	26 000 Value: $21.8K
Apr 07, 2025 Buy	Common Stock P-Purchase	Bagai Shaun Chief Executive Officer	CEO / President	10 000 Value: $8K
Apr 07, 2025 Buy	Common Stock P-Purchase	Bagai Shaun Chief Executive Officer	CEO / President	10 000 Value: $8K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Ryan Una S Director	Director	25 099 Value: $25.6K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Macfarlane K. Angela Director	Director	25 099 Value: $25.6K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Marton Laurence Director	Director	25 099 Value: $25.6K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Spiegel Robert J. Director	Director	25 099 Value: $25.6K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Ryan Una S Director	Director	25 099 Value: $25.6K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Macfarlane K. Angela Director	Director	25 099 Value: $25.6K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Marton Laurence Director	Director	25 099 Value: $25.6K
Oct 01, 2024 Buy	Stock Options (right to buy) A-Award	Spiegel Robert J. Director	Director	25 099 Value: $25.6K
Mar 06, 2024 Buy	Options A-Award	Gentry Leesa Chief Clinical Officer	Officer	190 000 Value: $321.1K
Mar 06, 2024 Buy	Options A-Award	Gentry Leesa Chief Clinical Officer	Officer	190 000 Value: $321.1K
Jan 19, 2024 Buy	Options	Gentry Leesa Chief Clinical Officer	Officer	60 159 Value: $65.0K
Jan 19, 2024 Buy	Options	Gentry Leesa Chief Clinical Officer	Officer	60 159 Value: $65.0K
Jun 01, 2023 Buy	Options	Gentry Leesa Chief Clinical Officer	Officer	62 500 Value: $131.9K
Jun 01, 2023 Buy	Options	Gentry Leesa Chief Clinical Officer	Officer	62 500 Value: $131.9K
Mar 15, 2023 Buy	Options	Kocak Ron Vp, Controller And Pao	Officer	15 875 Value: $52.2K
Aug 18, 2022 Buy	Options	Kocak Ron Vp, Controller And Pao	Officer	34 390 Value: $75.3K
Apr 22, 2022 Buy	Common Stock J-Other	Ryan Una S Director	Director	26 838 Value: $25.0K
Apr 22, 2022 Buy	Common Stock J-Other	Ryan Una S Director	Director	16 206 Value: $26.3K
Mar 03, 2022 Buy	Common Stock J-Other	Ryan Una S Director	Director	47 789 Value: $200.2K
Mar 03, 2022 Buy	Common Stock J-Other	Ryan Una S Director	Director	6 332 Value: $25.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RENOVORX, INC.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California....

Read Full Profile Here